Pembrolizumab combined with chemotherapy for advanced and recurrent endometrial cancer: A single-center retrospective study
{{output}}
Background/purpose: Immune checkpoint inhibitors have clinical benefits in patients with advanced or recurrent endometrial cancer, particularly those with deficient mismatch repair (dMMR) status. However, real-world data on the e... ...